Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs 3M Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $280.05 (market cap $39.89B), while 3M Company trades at $158.47 (market cap $82.16B). The key difference: 3M Company is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and 3M Company pays a 1.98% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MMM | |
|---|---|---|
Market Cap | $39.89B | $82.16B |
Sector | Health | Industrials |
52-Week High | $491.22 | $174.61 |
52-Week Low | $278.09 | $141.10 |
Enterprise Value | $38.15B | $90.56B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
3M (MMM) trades at $157.52, up 1.4% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with a 72.14% ROE and 13.03% net margin, though revenue has declined from 2022 peaks. Recent news highlights segment weakness in Consumer but strength in Safety & Industrial, alongside strategic partnerships like the Airbus A220 supply agreement.
Outlook is mixed: analyst consensus is cautious with a $148.75 price target below current levels, citing persistent consumer segment challenges. Investment appeal lies in dividend yield and cost optimization efforts, but risks include revenue stagnation and high debt levels. The stock faces headwinds from technical bearishness and modest growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
